Julien Taieb

发表

Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy

P. Laurent-Puig, D. Vernerey, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

O. Bouché, F. Retornaz, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.

C. Lepage, F. Ghiringhelli, J. Raoul, 2018, European journal of cancer.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies

N. Wolmark, E. Van Cutsem, A. Grothey, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).

F. Brunetti, A. Lièvre, C. Lepage, 2020, Annals of surgery.

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology.

E. Saad, E. Van Cutsem, J. Tabernero, 2021, Journal of the National Cancer Institute.

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study.

P. Laurent-Puig, J. Galon, A. Duval, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study

E. Van Cutsem, J. Tabernero, A. Grothey, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study

D. Vernerey, J. Taieb, R. Coriat, 2020, International journal of cancer.

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial.

F. Pruvot, M. Ychou, F. Bonnetain, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.

T. Mazard, Stefano Kim, D. Tougeron, 2024, European journal of cancer.

Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.

A. Takashima, P. García-Alfonso, P. Cuyle, 2024, European journal of cancer.

Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database.

N. Wolmark, R. Goldberg, J. Marshall, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.